Journal
Blood Advances
Publication Date
11-26-2024
Volume
8
Issue
22
First Page
5855
Last Page
5863
Document Type
Open Access Publication
DOI
10.1182/bloodadvances.2024013277
Rights and Permissions
Mehta A, Popplewell L, Collins GP, Smith SM, Flinn IW, Bartlett NL, Ghosh N, Hacohen-Kleiman G, Huo Y, Su-Feher L, Renard C, Advani R, Roschewski M. Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial. Blood Adv. 2024 Nov 26;8(22):5855-5863. doi: 10.1182/bloodadvances.2024013277. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution.
Recommended Citation
Mehta, Amitkumar; Popplewell, Leslie; Collins, Graham P; Smith, Sonali M; Flinn, Ian W; Bartlett, Nancy L; Ghosh, Nilanjan; Hacohen-Kleiman, Gal; Huo, Yanan; Su-Feher, Linda; Renard, Camille; Advani, Ranjana; and Roschewski, Mark, "Magrolimab plus rituximab in relapsed/refractory indolent non-Hodgkin lymphoma: 3-year follow-up of a phase 1/2 trial." Blood Advances. 8, 22. 5855 - 5863. (2024).
https://digitalcommons.wustl.edu/oa_4/4547
Additional Links
Supplemental material is available for this article at publisher site.